Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

An artist's impression of an Ebolavirus

A consortium set up to respond to the outbreak, including CEPI, Gavi, the World Health Organization (WHO) and Ugandan public health authorities, have outlined a range of measures.

They include the ring vaccination trial that will deploy candidate vaccines, including the University of Oxford’s ChAdOx1 biEBOV jab, against Sudan ebolavirus which is causing an ongoing outbreak in Uganda. The aim of the trial is to minimise hospitalisations and deaths. There are currently no licensed vaccines against Sudan ebolavirus.

Oxford’s vaccine has been designed to generate an immune response against two species, Ebola virus and Sudan ebolavirus, and is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca COVID-19 vaccine.

Read the full story on the University of Oxford webpage

Similar stories

EAVI2020: The Quest for an HIV Vaccine

In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.